alpha biomed glp 1 t GLP1 Medical Weight Loss GLP-1 10mg Vial (Semaglutide) |

Fillerfy Retatrutide 10MG is a premium-quality peptide product featuring an advanced triple-hormone receptor mechanism designed for next-generation metabolic and wellness support

Opinion: DHA's decision to end the coverage violates the Pentagon's own regulations regarding Tricare for Life beneficiaries.

This meta-analysis evaluates their effects on mortality and hospitalization in HFpEF

NATURAL METABOLIC BOOST - GLP-1 Daily Probiotic supports gut health and boosts GLP-1 production to help aid with appetite With probiotics like Akkermansia muciniphila, it curbs cravings, enhances digestion, supports metabolism, and sustains energy for men and women ENHANCE WEIGHT MANAGEMENT - Akkermansia helps activate GLP-1 naturally to boost nutrient absorption and promote satiation after eating

Others * Long-term metformin use * Proton pump inhibitors (reduce acid absorption) Pathophysiology * Impaired DNA synthesis megaloblastic anemia * Accumulation of methylmalonic acid nerve damage Clinical features Hematological * Fatigue, pallor * Shortness of breath * Megaloblastic anemia Neurological (key distinguishing feature) * Peripheral neuropathy (tingling, numbness) * Loss of vibration and position sense * Ataxia (unsteady gait) * Cognitive changes Severe untreated cases irreversible nerve damage Others * Glossitis (smooth, beefy red tongue) * Mild jaundice Investigations * Serum vitamin B12 * CBC macrocytic anemia ( MCV) * Blood film hypersegmented neutrophils * methylmalonic acid (specific for B12 deficiency) * homocysteine Differentiate from folate deficiency * Both megaloblastic anemia * Only B12 neurological symptoms Management Replacement therapy * Hydroxocobalamin (preferred IM) * Frequent doses initially, then maintenance * Oral B12 if mild and absorption intact Important rule Never give folate alone if B12 deficiency is possible may worsen neurological damage Prevention * Adequate diet (meat, eggs, dairy) * Supplementation in vegans * Monitor high-risk patients (elderly, post-surgery)

Robert Kushner, who helped bring them to market, breaks down how they actually work, who benefits most, and why they're a long-term commitment rather than a quick fix.